Pfizer CEO Ian Read said the company will return to "business as normal" on its drug pricing in January, after agreeing to hold off on price increases earlier this year following pressure from President Trump. (Peter Sullivan, The Hill)
Pfizer CEO Ian Read said the company will return to "business as normal" on its drug pricing in January, after agreeing to hold off on price increases earlier this year following pressure from President Trump. (Peter Sullivan, The Hill)